These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28111878)
1. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Creutzig U; Dworzak MN; Bochennek K; Faber J; Flotho C; Graf N; Kontny U; Rossig C; Schmid I; von Stackelberg A; Mueller JE; von Neuhoff C; Reinhardt D; von Neuhoff N Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111878 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985 [TBL] [Abstract][Full Text] [Related]
3. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100 [TBL] [Abstract][Full Text] [Related]
5. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child. Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972 [TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D; Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238 [TBL] [Abstract][Full Text] [Related]
7. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
9. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
11. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334 [TBL] [Abstract][Full Text] [Related]
12. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444 [TBL] [Abstract][Full Text] [Related]
13. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687 [TBL] [Abstract][Full Text] [Related]
14. [Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia]. Zhao YZ; Li HQ; Li DP; Li R; Qi JY; Wan CC; Zhou CL; Wang ZQ; Qian LS Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):32-4. PubMed ID: 12679008 [TBL] [Abstract][Full Text] [Related]
15. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165 [TBL] [Abstract][Full Text] [Related]
17. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis. Ma H; Yang J Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330 [TBL] [Abstract][Full Text] [Related]
18. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)]. Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006 [TBL] [Abstract][Full Text] [Related]
20. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype. Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]